Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954626 · ClinicalTrials.gov registry record · Phase 3
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
A Phase 3 study of Age-related Macular Degeneration and Eye Diseases, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT03954626: Completed Phase 3 study of Age-related Macular Degeneration and Eye Diseases, sponsored by Novartis Pharmaceuticals.
NCT03954626 is a Phase 3 study of Age-related Macular Degeneration and Eye Diseases that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03954626, a Phase 3 study of Age-related Macular Degeneration and Eye Diseases, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
Primary Outcome
Incidence between 20 and 24 h post-injection of clinically relevant treatment emergent changes in heart rate (HR), pulse rate (PR), QRS, and QTc (heart rate corrected QT using Fridericia's formula, QTcF) interval (ms). This is a composite endpoint capturing all 4 parameters and 3 time-points in one Outcome Measure.
Conditions Studied
Interventions
- BIOLOGICAL brolucuzumab 6 mg IVT
Study Locations (3)
Arizona
- Novartis Investigative Site - Phoenix
Texas
- Novartis Investigative Site - Abilene
Other
- Novartis Investigative Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-07 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 3 |
What the finished NCT03954626 record still lists
NCT03954626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,508-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which brolucuzumab 6 mg IVT is the first listed.
NCT03954626 reports a single indexed study location in Arizona, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT03954626 about?
NCT03954626 is a clinical study titled "Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD". The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
What is the current status of trial NCT03954626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2019-06-07. Estimated completion is 2019-07-31.
What conditions does trial NCT03954626 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Eye Diseases, Macular Degeneration, Retinal Degeneration, Retinal Diseases.
What interventions are being tested in trial NCT03954626?
The interventions under investigation include: brolucuzumab 6 mg IVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT03954626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03954626 being conducted?
This trial has 3 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03954626's enrollment target sits among peer trials
14 70th of 74 higher than 5 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
COMPLETED · Phase 3
-
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
COMPLETED · Phase 3
-
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
COMPLETED · Phase 3
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy